Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HB0017 in Moderate to Severe Plaque Psoriasis
NCT06477237Phase 3Completed
- Sponsor
- Huabo Biopharm
- Start
- Mar 2024
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in plaque psoriasis comparing HB0017 with placebo (2 arms). Primary endpoints: Psoriasis Area Severity Index 75 response at 12 weeks and Static Physician Global Assessment 0/1 response at 12 weeks. Started Mar 2024; status: completed.
02
Drugs
HB0017
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT06477237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06477237.